Inhibition of cell growth, induction of apoptosis and mechanism of action of the novel platinum compound cis-diaminechloro-[2-(diethylamino) ethyl 4-amino-benzoate, N4]-chloride platinum (II) monohydrochloride monohydrate

Investigational New Drugs

Volumn 22, Issue 1, 2004, Pages 3-16

  Mariggiò, Maria A ^a   Cafaggi, Sergio ^b   Ottone, Massimo ^c   Parodi, Brunella ^b   Vannozzi, Maria O ^c   Mandys, Vaclav ^d   Viale, Maurizio ^c  

^a UNIVERSITY OF BARI   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

^c UNIVERSITY OF GENOA   (Italy)

^d CHARLES UNIVERSITY   (Czech Republic)

Author keywords

Apoptosis; Cell lines; DPR; Growth inhibition; Mechanism of action

Indexed keywords

4',6 DIAMIDINO 2 PHENYLINDOLE; CISPLATIN; DIAMINECHLORO[N4 [2 (DIETHYLAMINO)ETHYL 4 AMINOBENZOATE]]CHLORIDE PLATINUM; DNA; ETHIDIUM BROMIDE; PLATINUM DERIVATIVE; PROCAINE; PROTEIN P53; UNCLASSIFIED DRUG;

AGAR GEL ELECTROPHORESIS; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL GROWTH; CELL PROLIFERATION; CONTROLLED STUDY; CROSS LINKING; DRUG MECHANISM; DRUG SCREENING; DRUG SELECTIVITY; DRUG SYNTHESIS; FEMALE; FLUORESCENCE; HUMAN; HUMAN CELL; INCIDENCE; LEUKEMIA CELL; LUNG SMALL CELL CANCER; NEUROBLASTOMA; OVARY CANCER; PRIORITY JOURNAL; STAINING; WESTERN BLOTTING;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; CELL SURVIVAL; CISPLATIN; DNA FRAGMENTATION; DRUG EVALUATION, PRECLINICAL; DRUG SCREENING ASSAYS, ANTITUMOR; ELECTROPHORESIS, AGAR GEL; FLUORESCENT DYES; HUMANS; INDOLES; INHIBITORY CONCENTRATION 50; MICE; MICROSCOPY, FLUORESCENCE; ORGANOPLATINUM COMPOUNDS; PROCAINE; TUMOR SUPPRESSOR PROTEIN P53; UP-REGULATION;

EID: 1042279669     PISSN: 01676997     EISSN: None     Source Type: Journal    
DOI: 10.1023/B:DRUG.0000006170.38419.c9     Document Type: Article

References (31)

1. Cafaggi S, Esposito M, Parodi B, Vannozzi MO, Viale M, Pellecchia C, Fulco RA, Merlo F, Zicca A, Cadoni A, Bignardi G: Synthesis and antitumour activity of a new cis-diammineplatinum(II) complex containing procaine hydrochloride. Anticancer Res 12: 2285-2292, 1992
2. Viale M, Cafaggi S, Parodi B, Esposito M: Cytotoxicity and cellular accumulation of a new cis-diammineplatinum(II) complex containing procaine in murine L1210 cells sensitive and resistant to cis-diamminedichloroplatinum (II). Cancer Chemother Pharmacol 35: 371-376, 1995
3. Viale M, Vannozzi MO, Merlo F, Cafaggi S, Parodi B, Esposito M: Cisplatin combined with the new cisplatin-procaine complex DPR: In vitro and in vivo studies. Eur J Cancer 32A: 2327-2333, 1996
4. Mandys V, Viale M, Cafaggi S, Esposito M: Neurotoxic effect of cisplatin and the cisplatin-procaine complex DPR studied in organotypic cultures of chick embryonic dorsal root ganglia. Anti-Cancer Drugs 9: 659-663, 1998
5. Zhang JG, Esposito M, Cafaggi S, Lindup WE: Comparison of the toxicities of cisplatin and a new cisplatin-procaine complex to rat renal cortical slices. Hum Exp Toxicol 15: 59-63, 1996
6. Pastrone I, Viale M, Cafaggi S, Mariggiò MA, Parodi A, Esposito M: Effect of the cisplatin-procaine complex DPR in combination with several anticancer agents on murine P388 leukemic cells in vitro and in vivo. Invest New Drugs 16: 297-302, 1999
7. Viale M, Pastrone I, Pellecchia C, Vannozzi MO, Cafaggi S, Esposito M: Combination of cisplatin-procaine complex DPR with anticancer drugs increases cytotoxicity against ovarian cancer cell lines. Anti-Cancer Drugs 9: 457-463, 1998
8. Boyd MR, Paull KD: Some practical considerations and applications of the National Cancer Institute in vitro anticancer drug discovery screen. Drug Dev Res 34: 91-109, 1995
9. Paull KD, Shoemaker RH, Hodes L, Monks A, Scudiero DA, Rubinstein L, Plowman J, Boyd MR: Display and analysis of patterns of differential activity of drugs against human tumor cell lines: Development of mean graph and compare algorithm. J Natl Cancer Inst 81: 1088-1092, 1989
10. Milner J: DNA damage, p53 and anticancer therapies. Nat Med 1: 879-880, 1995
11. Coluccia M, Boccarelli A, Mariggiò MA, Cardellicchio N, Caputo P, Intini FP, Natile G: Platinum(II) complexes containing iminoethers: A trans platinum antitumor agent. Chem-Biol Interact 98: 251-266, 1995
12. Lowe SW, Bodis S, McClatchey A, Remington L, Ruley HE, Fisher DE, Housman DE, Jacks T: p53 status and the efficacy of cancer therapy in vivo. Science 266: 807-810, 1994
13. Pistoia V, Roncella S, Di Celle PF, Sessarego M, Cutrona G. Cerruti G, Boccaccio GP, Grossi CE, Foà R, Ferrarini M: Emergence of a B-cell lymphoblastic lymphoma in a patient with B-cell chronic lymphocytic leukemia: Evidence for the single-cell origin of the two tumors. Blood 78: 797-804, 1991
14. Rogan AM, Hamilton TC, Joung RC, Klecker RW Jr, Ozols RF: Reversal of adriamycin resistance by verapamil in human ovarian cancer. Science 224: 994-996, 1984
15. Bénard J, Da Silva J, De Blois MC, Boyer P, Duvillard P, Chiric E, Riou G: Characterization of a human ovarian adenocarcinoma line, Igrov1, in tissue culture and in nude mice. Cancer Res 45: 4970-4979, 1985
16. Hussain RF, Nouri AME, Oliver RTD: A new approach for measurement of cytotoxicity using colorimetric assay. J Immunol Methods 160: 89-96, 1993
17. Maurich V, Sciortino T: Determinazione di aminofenazone e procaina in una forma farmaceutica mediante HPLC. Il Farmaco 35: 536-547, 1980
18. 2+-modified DNA: Rates of cross-linking reactions in cis-platinum-modified DNA. Nucleic Acid Res 21: 5846-5851, 1993
19. Sorenson CM, Barry MA, Eastman A: Analysis of events associated with cell cycle arrest at G2 phase and cell death induced by cisplatin. J Natl Cancer Inst 82: 749-755, 1990
20. Franks LM, Bollen A, Seeger RC, Stram DO, Matthay KK: Neuroblastoma in adults and adolescents. An indolent course with poor survival. Cancer 79: 2028-2035, 1997
21. Katzenstein HM, Cohn SL: Advances in the diagnosis and treatment of neuroblastoma. Curr Opin Oncol 10: 43-51, 1998
22. Hoffman PC, Mauer AM, Vokes EE: Lung cancer. The Lancet 355: 479-485, 2000
23. Sorenson CM, Eastman A: Influence of cis-diaminedichloro-platinum(II) on DNA synthesis and cell cycle progression in excision repair proficient and deficient Chinese hamster ovary cells. Cancer Res 48: 6703-6707, 1988
24. Chu G: Cellular responses to cisplatin. The roles of DNA-binding proteins and DNA repair. J Biol Chem 269: 787-790, 1994
25. Perez RP, Hamilton TC, Ozols RF, Young RC: Mechanisms and modulation of resistance to chemotherapy in ovarian cancer. Cancer 71: 1571-1580, 1993
26. Zlatanova J, Yaneva J, Leuba SH: Proteins that specifically recognize cisplatin-damaged DNA: A clue to anticancer activity of cisplatin. FASEB J 12: 791-799, 1998
27. Gonzales VM, Fuertes MA, Alonso C, Perez JM: Is cisplatin-induced cell death always produced by apoptosis? Mol Pharmacol 59: 657-663, 2001
28. Pestell KE, Hobbs SM, Titley JC, Kelland LR, Walton MI: Effect of p53 status on sensitivity to platinum complexes in a human ovarian cancer cell line. Mol Pharmacol 57: 503-511, 2000
29. +. J Med Chem 32: 128-136, 1989
30. Hollis LS, Sundquist WI, Burstyn JN, Heiger-Bernays WJ, Bellon SF, Ahmed KJ, Amundsen AR, Stern EW, Lippard SJ: Mechanistic studies of a novel class of trisubstituted platinum(II) antitumor agents. Cancer Res 51: 1866-1867, 1991
31. Viale M, Mariggiò MA, Coluccia M, Vannozzi MO, Esposito M: Interaction between the new cisplatin-derived compound DPR and DNA: Preliminary study (Abstract). Tumori 82: 30, 1996